TXG 10x Genomics Inc

Price (delayed)

$27.48

Market cap

$3.29B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.23

Enterprise value

$3.03B

10x Genomics is an American biotechnology company that designs and manufactures gene sequencing technology used in scientific research. It was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin ...

Highlights

10x Genomics's revenue has increased by 17% YoY

10x Genomics's debt has decreased by 10% YoY and by 3.3% QoQ

The company's quick ratio rose by 8% QoQ but it fell by 5% YoY

The company's net income has shrunk by 52% YoY and by 3.6% QoQ

TXG's EPS is down by 46% year-on-year and by 2.3% since the previous quarter

Sector: Healthcare

Industry: Health Information Services

Website: http://www.10xgenomics.com

Peers: NVCR NVAX

Key stats

What are the main financial stats of TXG

Market

Shares outstanding

119.71M

Market cap

$3.29B

Enterprise value

$3.03B

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

4.56

Price to sales (P/S)

5.25

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

4.84

Earnings

Revenue

$625.45M

EBIT

-$256.9M

EBITDA

-$210.4M

Free cash flow

-$73.75M

Per share

EPS

-$2.23

Free cash flow per share

-$0.62

Book value per share

$6.03

Revenue per share

$5.24

TBVPS

$7.56

Balance sheet

Total assets

$922.91M

Total liabilities

$204.08M

Debt

$92.18M

Equity

$718.83M

Working capital

$458.36M

Liquidity

Debt to equity

0.13

Current ratio

5.22

Quick ratio

4.26

Net debt/EBITDA

1.25

Margins

EBITDA margin

-33.6%

Gross margin

64.6%

Net margin

-42.3%

Operating margin

-43.9%

Efficiency

Return on assets

-27.6%

Return on equity

-35.3%

Return on invested capital

-44.3%

Return on capital employed

-31.6%

Return on sales

-41.1%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

TXG stock price

How has the 10x Genomics stock price performed over time

Intraday

4.53%

1 week

-0.4%

1 month

-24.4%

1 year

-49.11%

YTD

-50.89%

QTD

-26.78%

Financial performance

How have 10x Genomics's revenue and profit performed over time

Revenue

$625.45M

Gross profit

$403.84M

Operating income

-$274.84M

Net income

-$264.3M

Gross margin

64.6%

Net margin

-42.3%

TXG's operating income has dropped by 54% year-on-year and by 3.6% since the previous quarter

The company's net income has shrunk by 52% YoY and by 3.6% QoQ

10x Genomics's operating margin has decreased by 32% YoY and by 2.3% QoQ

10x Genomics's net margin has decreased by 30% YoY and by 2.7% QoQ

Growth

What is 10x Genomics's growth rate over time

Valuation

What is 10x Genomics stock price valuation

P/E

N/A

P/B

4.56

P/S

5.25

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

4.84

TXG's EPS is down by 46% year-on-year and by 2.3% since the previous quarter

The P/B is 67% below the 5-year quarterly average of 13.7 and 39% below the last 4 quarters average of 7.5

TXG's equity is down by 10% year-on-year and by 3% since the previous quarter

The stock's price to sales (P/S) is 78% less than its 5-year quarterly average of 23.4 and 44% less than its last 4 quarters average of 9.4

10x Genomics's revenue has increased by 17% YoY

Efficiency

How efficient is 10x Genomics business performance

The return on invested capital has dropped by 79% year-on-year and by 8% since the previous quarter

The ROE has plunged by 60% YoY and by 7% from the previous quarter

TXG's ROA has plunged by 60% YoY and by 6% from the previous quarter

TXG's ROS is down by 30% year-on-year and by 2.2% since the previous quarter

Dividends

What is TXG's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for TXG.

Financial health

How did 10x Genomics financials performed over time

The current ratio has grown by 11% from the previous quarter but it has contracted by 2.8% YoY

TXG's total assets is down by 9% year-on-year and by 4.4% since the previous quarter

10x Genomics's debt is 87% lower than its equity

TXG's equity is down by 10% year-on-year and by 3% since the previous quarter

10x Genomics's debt has decreased by 10% YoY and by 3.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.